Zoetis Inc.
Zoetis Inc. Announces Issuance of Senior Notes
Summary
On August 11, 2025, Zoetis Inc. announced the issuance and sale of $850,000,000 aggregate principal amount of 4.150% Senior Notes due 2028 and $1,000,000,000 aggregate principal amount of 5.000% Senior Notes due 2035 under an Underwriting Agreement and Indenture dated January 28, 2013, supplemented by a Seventh Supplemental Indenture dated August 18, 2025. The offering was registered on a Registration Statement on Form S-3 (File No. 333-289241). Financial statements and exhibits are furnished as part of this filing.
Profitelligence Alerts
Get alerts for ZTS
Be first to know when Zoetis Inc. files with the SEC.
Filing Categories
Exhibits (5)
Advertisement
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Official SEC Documents
Advertisement